Abstract:Incretin is a hormone released from the L -cells in the gut wall under the stimulation of food and can promote the insulin secretion.The related agents used in the clinic mainly include two types , the gluca-gon-like peptide-1 ( GLP-1 ) receptor agonists and dipeptidyl pepti-dase -4 ( DPP -4 ) inhibitors.Pharmacokinetic/pharmacodynamic ( PK/PD) models of incretin related agents can be useful tools in optimal drug therapy in patients and support the design of future clinical trials.Meanwhile , a mechanism-based model can be more powerful at predic-ting physiological characteritics and the probability of successful outcome of anti -diabetic treatment for different dosage regimens of the drugs , which will be beneficial for new drugs development and dosage regimens regulation.The present review is focused on the mechanism -based PK/PD models of representative drugs which belong to GLP -1 receptor agonists and DPP-4 inhibitors.

Review on pharmacokinetic/pharmacodynamic models of the related agents of incretin